Sage Therapeutics Inc (SAGE) — Cash Flow-to-Debt Ratio
Sage Therapeutics Inc (SAGE) has a Cash Flow-to-Debt Ratio of -1.08x as of June 2025, meaning its operating cash flow of $-58.69 Million could theoretically repay -1% of its total liabilities ($54.19 Million) in one year. Check Sage Therapeutics Inc total reinvestment intensity to assess the company's total reinvestment commitment from operating cash flow.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Sage Therapeutics Inc Cash Flow-to-Debt Ratio (2012–2024)
Historical debt coverage capacity for Sage Therapeutics Inc across 13 annual periods. Also explore Sage Therapeutics Inc (SAGE) total assets for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Sage Therapeutics Inc (2012–2024)
Year-by-year debt coverage analysis for Sage Therapeutics Inc. For market capitalisation and broader financial context, see SAGE market cap.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -3.25x | $-267.19 Million | $82.13 Million | ▲ +50.2% |
| 2023 | -6.53x | $-540.59 Million | $82.75 Million | ▼ -47.5% |
| 2022 | -4.43x | $-460.04 Million | $103.85 Million | ▼ -12.8% |
| 2021 | -3.93x | $-378.18 Million | $96.26 Million | ▼ -151.4% |
| 2020 | 7.64x | $664.28 Million | $86.91 Million | ▲ +301.7% |
| 2019 | -3.79x | $-528.71 Million | $139.50 Million | ▼ -30.5% |
| 2018 | -2.90x | $-260.67 Million | $89.73 Million | ▲ +27.9% |
| 2017 | -4.03x | $-219.28 Million | $54.46 Million | ▼ -22.2% |
| 2016 | -3.30x | $-118.68 Million | $36.01 Million | ▲ +28.6% |
| 2015 | -4.61x | $-70.68 Million | $15.32 Million | ▼ -32.7% |
| 2014 | -3.48x | $-27.04 Million | $7.78 Million | ▼ -695.1% |
| 2013 | -0.44x | $-17.52 Million | $40.07 Million | ▲ +19.7% |
| 2012 | -0.54x | $-8.93 Million | $16.39 Million | — |